AN2 Therapeutics, Inc. (ANTX) Misses Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts ANTX Hot Sheet
Join SI Premium – FREE
AN2 Therapeutics, Inc. (NASDAQ: ANTX) reported Q1 EPS of ($0.29), $0.06 worse than the analyst estimate of ($0.23).
For earnings history and earnings-related data on AN2 Therapeutics, Inc. (ANTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orion Marine Group (ORN) Tops Q3 EPS by 3c ; Offers Guidance
- FFB Bancorp (FFBB) Tops Q3 EPS by 161c
- First Carolina Financial Services, Inc. (FCBM) Reports Q3 EPS of $0.26
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
